C57BL/6J-Appem1Bdes/H

Status

Available to order

EMMA IDEM:17014
Citation informationRRID:IMSR_EM:17014 

Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.

 
International strain nameC57BL/6J-Appem1Bdes/H
Alternative nameC57BL/6J-App/H
Strain typeEndonuclease-mediated
Allele/Transgene symbolAppem1Bdes
Gene/Transgene symbolApp

Information from provider

ProviderBart De Strooper
Provider affiliationUK Dementia Research Institute, UCL Institute of Neurology
Genetic informationThis strain is a knock-in model harboring a humanize Aβ sequence (G601R, F606Y and R609H mutations APP695) to the rodent APP exon 16 and two silent mutations, one deleting a EcoRI Restriction site. We validated the different APP processing in human, mouse and rat brain by western blot analysis. The ratio of β-CTF over full length APP in human samples is 4.8 (p
Phenotypic informationHomozygous:
Full length APP and total APP-CTF levels were unchanged in mice, but APP-β-CTF signals increased 4.2 fold in APPhu/hu mice. Conversely, APP-α-CTF signals decreased 0.7 fold in APPhu/hu mice.

Heterozygous:
No overt phenotype
Breeding historyMaintained on C57BL/6J
References
  • Modeling the β-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimer's disease.;Serneels Lutgarde, T'Syen Dries, Perez-Benito Laura, Theys Tom, Holt Matthew G, De Strooper Bart, ;2020;Molecular neurodegeneration;15;60; 33076948
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredno
Immunocompromisedno

Information from EMMA

Archiving centreMary Lyon Centre at MRC Harwell, Oxford, United Kingdom

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

IMPC phenotypes (gene matching)
  • preweaning lethality, incomplete penetrance / IMPC
  • increased cornea thickness / IMPC
  • decreased total retina thickness / IMPC
  • short tibia / IMPC
  • increased circulating calcium level / IMPC
  • increased blood urea nitrogen level / IMPC
  • decreased grip strength / IMPC
MGI phenotypes (gene matching)
  • amyloidosis / MGI
  • muscle degeneration / MGI
  • decreased corpus callosum size / MGI
  • abnormal telencephalon morphology / MGI
  • decreased body weight / MGI
  • increased anxiety-related response / MGI
  • abnormal locomotor behavior / MGI
  • hyperactivity / MGI
  • hypoactivity / MGI
  • decreased exploration in new environment / MGI
  • abnormal cued conditioning behavior / MGI
  • abnormal spatial learning / MGI
  • reduced long term potentiation / MGI
  • impaired swimming / MGI
  • intracerebral hemorrhage / MGI
  • abnormal learning/memory/conditioning / MGI
  • abnormal fear/anxiety-related behavior / MGI
  • abnormal motor capabilities/coordination/movement / MGI
  • premature death / MGI
  • abnormal brain morphology / MGI
  • no abnormal phenotype detected / MGI
  • decreased brain weight / MGI
  • gliosis / MGI
  • absent corpus callosum / MGI
  • abnormal brain commissure morphology / MGI
  • abnormal long term potentiation / MGI
  • abnormal emotion/affect behavior / MGI
  • increased thigmotaxis / MGI
  • abnormal active avoidance behavior / MGI
  • abnormal long term object recognition memory / MGI
  • abnormal neuron morphology / MGI
  • no phenotypic analysis / MGI
  • abnormal locomotor activation / MGI
  • amyloid beta deposits / MGI
  • astrocytosis / MGI
  • nervous system phenotype / MGI
  • impaired passive avoidance behavior / MGI
  • myositis / MGI
  • homeostasis/metabolism phenotype / MGI
  • growth/size/body region phenotype / MGI
  • behavior/neurological phenotype / MGI
  • abnormal cell physiology / MGI
  • decreased hippocampal commissure size / MGI
  • decreased anterior commissure size / MGI
  • abnormal spatial reference memory / MGI
  • hematoma / MGI
  • microgliosis / MGI
  • increased variability of skeletal muscle fiber size / MGI
  • centrally nucleated skeletal muscle fibers / MGI
  • abnormal synapse morphology / MGI
  • decreased grip strength / MGI
  • altered susceptibility to induced thrombosis / MGI
  • abnormal circadian behavior / MGI

Literature references

  • Modeling the β-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimer's disease.;Serneels Lutgarde, T'Syen Dries, Perez-Benito Laura, Theys Tom, Holt Matthew G, De Strooper Bart, ;2020;Molecular neurodegeneration;15;60; 33076948

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable), as well as a CRISPR surcharge.

More details on pricing and delivery times

Practical information

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
MTA will be issued after an order has been submitted.

EMMA conditions
Legally binding conditions for the transfer

Right strain for your research?

The information provided on this page is, to the best of EMMA’s knowledge, based on data supplied by the original provider. End users are responsible for reviewing these details and for validating the strain and its suitability for their experimental use.​
Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).